Shanghai

Boehringer Ingelheim BioXcellence™ – Shanghai, China

Boehringer Ingelheim has made its strategic move to become a leader for contract development and manufacturing of monoclonal antibodies and recombinant proteins in China. Since 2014, Boehringer Ingelheim Biopharmaceuticals China has been running its production lines at 100L and 500L scales for GMP clinical material supply at BioLab, Shanghai. From Q1/2017 onwards, a larger GMP facility at 2,000L manufacturing scale - Oasis -  for clinical and commercial supply will be in operation. Both BioLab and Oasis are based on disposable technology.
Read more

 

What Shanghai can offer you:

  • Flexible, fully disposable GMP facility for clinical and early commercial supply up to 2,000L
  • Globally established disposable concept enabling smooth transfers to all and between different Boehringer Ingelheim sites
  • Upstream and downstream process development
  • Process transfer – all phases of clinical and commercial products
  • Clinical and commercial scale manufacturing
  • Project uptake at every step in project development
  • State-of-the-art Fill & Finish capabilities
  • And more ...

See below for our latest news about Boehringer Ingelheim Biopharmaceuticals in China:

News:

17.01.2019

Boehringer Ingelheim Biopharmaceuticals China expands commercial manufacturing capacities

03.09.2018

Boehringer Ingelheim Biopharmaceuticals China supports BeiGene in its China NDA submission of anti-PD-1 antibody, tislelizumab

20.08.2018

Development partner Boehringer Ingelheim supplies clinical material manufactured in China for new cancer drug

09.01.2018

BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab

07.07.2017

Shanghai’s Party Secretary Visits Oasis Site of Boehringer Ingelheim BioChina

16.05.2017

Boehringer Ingelheim Inaugurates World-Class Biopharmaceutical Manufacturing Facility in China

26.09.2016

BeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody Supplied by the Boehringer Ingelheim Biopharmaceutical Site in China

11.08.2016

CANbridge signs agreement with Boehringer Ingelheim to manufacture inhibitory antibody, CAN-017, for esophageal squamous cell cancer

24.03.2016

Zai Lab signs a supply agreement with Boehringer Ingelheim Biopharma

17.02.2016

Boehringer Ingelheim to launch China's first biopharma CMO pilot project

13.01.2016

BeiGene’s U.S. IND becomes active for BGB-A317, a humanized PD-1 Inhibitor monoclonal antibody

25.08.2015

Boehringer Ingelheim China Biopharmaceuticals Site celebrates milestone to bolster Shanghai’s innovation center ambition

04.09.2014

Boehringer Ingelheim and BeiGene announce strategic partnership agreement in China

06.06.2013

Boehringer Ingelheim pioneers biopharmaceuticals move to China

Boehringer Ingelheim Biopharmaceuticals in China (whitepaper)

Biopharmaceutical contract manufacturing at Boehringer Ingelheim Shanghai

Contact Us

Boehringer Ingelheim BioXcellence - Contact Us

Do you have any inquiries, questions or comments? Please get in touch with us.